新消费概念股普遍活跃，截至发稿，蜜雪集团(02097)涨7.29%，报423.8港元；老铺黄金(06181)涨 5.02%，报691港元；锅圈(02517)涨5.09%，报3.51港元；泡泡玛特(09992)涨3.89%，报200.4港元；布鲁 可(00325)涨2.96%，报71.3港元；沪上阿姨(02589)涨2.78%，报94.15港元。 东兴证券指出，2025年新消费投资情绪经历了从狂热到谨慎的过程。2026年政策的持续加码有望提振消 费信心，对于新消费领域的投资将从纯粹的短期叙事回归商业模式与盈利壁垒，投资者会倾向寻找那些 真正能够构建稳固的商业模式，盈利模式可持续的公司。该行认为新消费行业会向三个趋势和两个维度 的方向发展。三个趋势是健康化、新实用主义和情绪消费，两个维度是智能化和消费出海，建议积极关 注相关方向的投资机会。 消息面上，近期消费有关政策频出。中央经济工作会议提出八项明年经济工作的重点任务，其中第一项 重点任务为坚持内需主导，建设强大国内市场。12月15日，《求是》杂志发表文章《扩大内需是战略之 举》，文章强调要"牢牢把握扩大内需这一战略基点"，阐明了扩大内需对发展全局的基础支撑作用 ...

东兴证券指出，2025年新消费投资情绪经历了从狂热到谨慎的过程。2026年政策的持续加码有望提振消 费信心，对于新消费领域的投资将从纯粹的短期叙事回归商业模式与盈利壁垒，投资者会倾向寻找那些 真正能够构建稳固的商业模式，盈利模式可持续的公司。该行认为新消费行业会向三个趋势和两个维度 的方向发展。三个趋势是健康化、新实用主义和情绪消费，两个维度是智能化和消费出海，建议积极关 注相关方向的投资机会。 智通财经APP获悉，新消费概念股普遍活跃，截至发稿，蜜雪集团(02097)涨7.29%，报423.8港元；老铺 黄金(06181)涨5.02%，报691港元；锅圈(02517)涨5.09%，报3.51港元；泡泡玛特(09992)涨3.89%，报 200.4港元；布鲁可(00325)涨2.96%，报71.3港元；沪上阿姨(02589)涨2.78%，报94.15港元。 消息面上，近期消费有关政策频出。中央经济工作会议提出八项明年经济工作的重点任务，其中第一项 重点任务为坚持内需主导，建设强大国内市场。12月15日，《求是》杂志发表文章《扩大内需是战略之 举》，文章强调要"牢牢把握扩大内需这一战略基点"，阐明了扩大内需对发 ...

消息面上，沪上阿姨此前发布公告，将于2026年2月4日派发2025年中期股息每10股7.43755港元。国泰 海通证券发布研报称，沪上阿姨实施"一体两翼"战略，其中"一体"为"沪上阿姨"主品牌，测算国内开店 空间1.8万家；"两翼"分别为"茶瀑布"和海外市场，测算"茶瀑布"国内开店空间超5000家；海外目前进军 马来西亚和美国，处于发展初期，成长潜力较大。 沪上阿姨(02589)午后急升逾7%，截至发稿，涨3.03%，报95.25港元，成交额3685.74万港元。 ...

消息面上，沪上阿姨此前发布公告，将于2026年2月4日派发2025年中期股息每10股7.43755港元。国泰 海通证券发布研报称，沪上阿姨实施"一体两翼"战略，其中"一体"为"沪上阿姨"主品牌，测算国内开店 空间1.8万家；"两翼"分别为"茶瀑布"和海外市场，测算"茶瀑布"国内开店空间超5000家；海外目前进军 马来西亚和美国，处于发展初期，成长潜力较大。 智通财经APP获悉，沪上阿姨(02589)午后急升逾7%，截至发稿，涨3.03%，报95.25港元，成交额 3685.74万港元。 ...

Group 1 - The core viewpoint of the news is that Baoyi Pharmaceutical-B (02589) has successfully listed on the Hong Kong Stock Exchange, with a significant first-day increase of 138.82%, leading to a market capitalization exceeding HKD 20 billion [1] - As of the latest update, Baoyi Pharmaceutical-B's stock price rose by 3.79% to HKD 68.45, with a trading volume of HKD 18.38 million [1] - The company focuses strategically on four key areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [1] Group 2 - Baoyi Pharmaceutical has developed a unique "pyramid" pipeline structure, which is supported by a combination of scenario-driven strategic choices, technological barriers in synthetic biology, and industrialization advantages of total cost leadership [2] - The base of the "pyramid" pipeline consists of products with short clinical cycles, low costs, and high market demand certainty, such as the approved SJ02 and the NDA-submitted KJ017 [2] - This product focus allows Baoyi Pharmaceutical to quickly generate stable sales and cash flow, providing the company with self-sustaining capabilities and alleviating the common financing anxiety faced by 18A enterprises [2]

Group 1: Market Movements - Baoji Pharmaceutical-B (02659) surged over 3.2% amid its debut on the Hong Kong Stock Exchange, closing up 138.82% on its first day, with a market capitalization exceeding HKD 20 billion [1] - New Energy (01799) and Xinyi Solar (00968) saw declines of 3.01% and 3.67% respectively, as the photovoltaic sector faced weakness, with rumors of a 30 billion yuan investment for capacity storage by major companies [1] - Xpeng Motors-W (09868) and Li Auto-W (02015) dropped 4.88% and 2.67% respectively, following data from the China Association of Automobile Manufacturers indicating a month-on-month increase in production and sales [1] Group 2: Company-Specific News - Bolek Vision Cloud-B (02592) experienced a significant drop of nearly 15%, having previously doubled in price over 10 trading days, as it announced a new drug trial application to the FDA [2] - Hu Shang Ayi (02589) rose nearly 6% as Nayuki Tea expanded into the U.S. market, enhancing the international presence of Chinese tea brands [2] - Gold stocks fell sharply, with Zijin Mining (02899) and Shandong Gold (01787) declining by 4.29% and 4.94% respectively, following a report on the Bloomberg Commodity Index's upcoming rebalancing [2] Group 3: Cryptocurrency and Technology - Cryptocurrency ETFs faced significant declines, with notable drops in Bitcoin and Ethereum-related funds, as Bitcoin fell 3.3% from its record high, reflecting market pressures amid weak liquidity [3] - Oracle (ORCL.US) continued its downward trend, dropping 2.66% due to delays in delivering AI data centers for OpenAI, attributed to labor and material shortages [6] - Nvidia (NVDA.US) saw a slight increase of 0.73% after announcing the release of its third-generation language model, aimed at writing and programming tasks [6]

消息上，国泰海通证券发布研报称，首次覆盖给予沪上阿姨"增持"评级，目标价116.56港元，沪上阿姨 旗下拥有"沪上阿姨""茶瀑布"和"沪咖"三大品牌，形成覆盖不同价格带与消费群体的品牌矩阵。公司凭 借高效的研发与加盟模式快速拓展市场，尤其在北方具备优势。公司实施"一体两翼"战略，多品牌开店 潜力较大。此外，咖啡业务经历调整升级，目前整合进沪上阿姨主品牌，有望贡献单店增量。 本文源自：格隆汇 12月16日，沪上阿姨(2589.HK)盘初曾直线拉升涨超10%，股价重回百港元上方，最新总市值107亿港 元。 ...

沪上阿姨(2589.HK)盘初曾直线拉升涨超10%，股价重回百港元上方，最新总市值107亿港元。 消息上，国泰海通证券发布研报称，首次覆盖给予沪上阿姨"增持"评级，目标价116.56港元，沪上阿姨旗下拥有"沪上阿姨""茶瀑布"和"沪咖"三大品牌，形 成覆盖不同价格带与消费群体的品牌矩阵。公司凭借高效的研发与加盟模式快速拓展市场，尤其在北方具备优势。公司实施"一体两翼"战略，多品牌开店潜 力较大。此外，咖啡业务经历调整升级，目前整合进沪上阿姨主品牌，有望贡献单店增量。 ...

每经AI快讯，宝济药业-B(02589.HK)逆市涨近4%，截至发稿，涨3.79%，报68.45港元，成交额1837.76 万港元。 ...

Group 1 - The core viewpoint of the news is that Baoyi Pharmaceutical-B (02589) has seen a significant stock price increase of nearly 5% following the approval of its product Shengnuo Wa® for market launch and the submission of NDA for KJ017 [1] - Baoyi Pharmaceutical-B officially listed on the Hong Kong Stock Exchange, with its stock price rising by 138.82% on the first day of trading, resulting in a market capitalization exceeding HKD 20 billion [1] - The company focuses strategically on four key areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [1] Group 2 - Baoyi Pharmaceutical has developed a unique "pyramid" pipeline layout, driven by strategic choices, technological barriers in synthetic biology, and industrial cost leadership [2] - The base of the "pyramid" pipeline consists of products with short clinical cycles, low costs, and high market demand certainty, such as the approved SJ02 and the submitted NDA for KJ017 [2] - This product focus allows Baoyi Pharmaceutical to quickly generate stable sales and cash flow, providing the company with self-sustaining capabilities and alleviating common financing anxieties faced by 18A companies [2]